Page last updated: 2024-09-04

moxifloxacin and azomycin

moxifloxacin has been researched along with azomycin in 40 studies

Compound Research Comparison

Studies (moxifloxacin)	Trials (moxifloxacin)	Recent Studies (post-2010) (moxifloxacin)	Studies (azomycin)	Trials (azomycin)	Recent Studies (post-2010) (azomycin)
3,157	552	1,690	4,790	418	1,580

Research

Studies (40)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (10.00)	29.6817
2010's	31 (77.50)	24.3611
2020's	5 (12.50)	2.80

Authors

Authors	Studies
Andries, K; Chauffour, A; Jarlier, V; Ji, B	1
Chauffour, A; Jarlier, V; Ji, B; Lefrançois, S; Robert, J; Truffot, C	1
Coates, AR; Hu, Y; Mitchison, DA	1
Almeida, D; Grosset, JH; Nuermberger, E; Rosenthal, I; Tasneen, R; Tyagi, S; Williams, KN	1
Cole, ST; Dhar, N; Ha, YH; Hartkoorn, RC; Sala, C; Schneider, P; Zhang, M	1
Hutson, S	1
Ginsberg, A	1
Bishai, WR; Davis, SL; Harper, J; Jain, SK; Kramnik, I; Nuermberger, EL; Pomper, MG; Skerry, C; Tasneen, R; Weir, M	1
Roehr, B	1
Becker, P; Dawson, R; Diacon, AH; Donald, PR; Everitt, D; Mendel, CM; Spigelman, MK; Symons, G; van Niekerk, C; Venter, A; von Groote-Bidlingmaier, F; Winter, H	1
Kmietowicz, Z	1
Cole, ST; Hartkoorn, RC; Lechartier, B	1
Schaberg, T	1
Dawson, R; Diacon, A	1
Jeong, BH; Koh, WJ; Kwon, YS	1
Garcia-Prats, AJ; Hesseling, AC; Schaaf, HS; Seddon, JA	1
Diao, C; Liang, L; Liu, X; Wang, L; Xu, Y; Zhang, J; Zhang, S	1
Bagcchi, S	1
Amoabeng, O; Mdluli, KE; Minkowski, A; Nuermberger, EL; Tasneen, R; Upton, AM; Williams, K	1
Burger, DA; Conradie, A; Dawson, R; Diacon, AH; Donald, PR; Eisenach, K; Everitt, D; Ive, P; Mendel, CM; Ntinginya, NE; Page-Shipp, L; Pym, A; Reither, K; Schall, R; Spigelman, M; van Niekerk, C; Variava, E; Venter, A; von Groote-Bidlingmaier, F	1
Migliori, GB; Sotgiu, G	1
Centis, R; D'Ambrosio, L; Fuentes, Z; Migliori, GB; Sotgiu, G; Tiberi, S; Zumla, A	1
Das, SC; Krittaphol, W; Momin, MAM; Thien, SJ	1
Cooke, G; Fortunak, J; Gotham, D; Hill, A; Khoo, S; Nytko, FE; Pozniak, A	1
Mendel, C; Murray, S; Spigelman, M	1
Converse, PJ; Li, SY; Mdluli, K; Nuermberger, EL; Soni, H; Tasneen, R; Tyagi, S	1
Dong, L; Fu, Y; Huang, H; Huo, F; Jing, W; Li, Y; Ma, Y; Pang, Y; Zhao, L; Zong, Z	1
Jo, KW; Nam, GB; Shim, TS; Yoon, HY	1
Aguilar-Ayala, DA; Cnockaert, M; Gonzalez-Y-Merchand, J; Martin, A; Palomino, JC; Vandamme, P	1
de Miranda Silva, C; Drusano, GL; Hajihosseini, A; Louie, A; Myrick, J; Nole, J; Schmidt, S	1
Khalid, UK; Mathuria, KK; Munjal, SK; Myneedu, VP; Puri, MM; Sarin, R; Singla, N; Singla, R; Verma, A; Vohra, V	1
Bethunaickan, R; Chandramohan, Y; Padmanaban, V; Ranganathan, UD; Swaminathan, S; Tripathy, S	1
Del Parigi, A; Everitt, D; Li, H; Li, M; Mendel, C; Nedelman, JR; Salinger, DH	1
Bendet, P; Berg, A; Cirrincione, K; Deshpande, D; Gumbo, T; Hanna, D; Hermann, D; Magombedze, G; Martin, K; Romero, K; Srivastava, S; van Zyl, J	1
Burger, DA; Conradie, A; Conradie, F; Crook, AM; Dawson, R; Diacon, AH; Everitt, DE; Haraka, F; Li, M; Mendel, CM; Ntinginya, NE; Okwera, A; Rassool, MS; Reither, K; Sebe, MA; Spigelman, M; Staples, S; Tweed, CD; van Niekerk, CH; Variava, E	1
Furin, J; McKenna, L	1
de Jong, BC; Decroo, T; Lynen, L; Piubello, A; Van Deun, A	1
El-Amin, W; Everitt, D; Li, M; Makhene, MK; Nedelman, J; Osborn, B; Saviolakis, GA; Yang, TJ	1
de Jong, BC; Decroo, T; Gils, T; Lynen, L; Van Deun, A	1
Carr, W; Converse, PJ; Dartois, V; Dooley, KE; Garcia, A; Kurbatova, E; Nuermberger, EL; Stout, JE; Tasneen, R; Vernon, AA; Zimmerman, MD	1

Reviews

5 review(s) available for moxifloxacin and azomycin

Article	Year
[Tuberculosis: new treatment options and updated recommendations]. Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:14 Topics: Antitubercular Agents; Aza Compounds; Cross-Sectional Studies; Diagnosis, Differential; Diarylquinolines; Fluoroquinolones; Germany; Humans; Moxifloxacin; Nitroimidazoles; Oxazoles; Prognosis; Quinolines; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2013
PA-824 , moxifloxacin and pyrazinamide combination therapy for tuberculosis. Expert opinion on investigational drugs, 2013, Volume: 22, Issue:7 Topics: Animals; Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Molecular Structure; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis, Pulmonary	2013
Tuberculosis: clinical trials and new drug regimens. Current opinion in pulmonary medicine, 2014, Volume: 20, Issue:3 Topics: Acetamides; Adamantane; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Administration Schedule; Drug Design; Ethylenediamines; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Oxazolidinones; Spiro Compounds; Thiazines; Tuberculosis; Tuberculosis, Multidrug-Resistant	2014
Managing multidrug-resistant tuberculosis in children: review of recent developments. Current opinion in infectious diseases, 2014, Volume: 27, Issue:3 Topics: Antitubercular Agents; Child; Child, Preschool; Directly Observed Therapy; Drug Administration Schedule; Ethionamide; Fluoroquinolones; Humans; Infant; Moxifloxacin; Nitroimidazoles; Practice Guidelines as Topic; Prevalence; Pyrazinamide; Risk Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant	2014
Pretomanid for tuberculosis: a systematic review. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:1 Topics: Antitubercular Agents; Humans; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2022

Trials

5 trial(s) available for moxifloxacin and azomycin

Article	Year
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet (London, England), 2012, Sep-15, Volume: 380, Issue:9846 Topics: Adult; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Prospective Studies; Pyrazinamide; Quinolines; Sputum; Tuberculosis, Pulmonary; Young Adult	2012
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul Lancet (London, England), 2015, May-02, Volume: 385, Issue:9979 Topics: Adolescent; Adult; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2015
Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:10 Topics: Antitubercular Agents; Computer Simulation; Diarylquinolines; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Heart Rate; Humans; Linezolid; Long QT Syndrome; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant	2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:12 Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Uganda	2019
Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy Volunteers. Clinical pharmacology in drug development, 2021, Volume: 10, Issue:6 Topics: Adolescent; Adult; Antitubercular Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Nitroimidazoles; Young Adult	2021

Other Studies

30 other study(ies) available for moxifloxacin and azomycin

Article	Year
Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:4 Topics: Acetamides; Animals; Anti-Infective Agents; Aza Compounds; Diarylquinolines; Female; Fluoroquinolones; Leprosy; Linezolid; Mice; Moxifloxacin; Mycobacterium leprae; Nitroimidazoles; Oxazolidinones; Quinolines	2006
In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:6 Topics: Acetamides; Amikacin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Foot; In Vitro Techniques; Linezolid; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium ulcerans; Nitroimidazoles; Oxazolidinones; Quinolines; Rifampin; Streptomycin; Survival Analysis; Time Factors	2006
Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2008, Volume: 12, Issue:1 Topics: Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Dose-Response Relationship, Drug; Fluoroquinolones; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Time Factors	2008
Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:4 Topics: Animals; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis, Pulmonary	2008
Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:10 Topics: Antitubercular Agents; Aza Compounds; Fluoroquinolones; Isoniazid; Meropenem; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Streptomycin; Thienamycins	2010
Half-century-old TB drugs get a facelift in new cocktails. Nature medicine, 2010, Volume: 16, Issue:12 Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Discovery; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis	2010
The TB Alliance: overcoming challenges to chart the future course of TB drug development. Future medicinal chemistry, 2011, Volume: 3, Issue:10 Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Diarylquinolines; Drug Evaluation, Preclinical; Fluoroquinolones; Humans; Models, Organizational; Moxifloxacin; Nitroimidazoles; Quinolines; Tuberculosis	2011
Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. The Journal of infectious diseases, 2012, Feb-15, Volume: 205, Issue:4 Topics: Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Fluoroquinolones; Gene Expression Profiling; Genes, Bacterial; Granuloma; Hypoxia; Immunohistochemistry; Male; Mice; Mice, Inbred C3H; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Positron-Emission Tomography; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis	2012
Trial tests new combination of drugs to treat tuberculosis. BMJ (Clinical research ed.), 2012, Mar-20, Volume: 344 Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Quinolines; Research Support as Topic; Tuberculosis; United States	2012
New drug combination for TB is tested in unique trial. BMJ (Clinical research ed.), 2012, Jul-25, Volume: 345 Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Combinations; Fluoroquinolones; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis	2012
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:11 Topics: Adamantane; Antitubercular Agents; Aza Compounds; Diarylquinolines; Drug Combinations; Drug Synergism; Ethambutol; Ethylenediamines; Fluoroquinolones; Isoniazid; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Spiro Compounds; Thiazines; Thienamycins	2012
LC-MS/MS method for the simultaneous determination of PA-824, moxifloxacin and pyrazinamide in rat plasma and its application to pharmacokinetic study. Journal of pharmaceutical and biomedical analysis, 2014, Volume: 97 Topics: Animals; Chromatography, Liquid; Drug Interactions; Fluoroquinolones; Limit of Detection; Metronidazole; Moxifloxacin; Nitroimidazoles; Plasma; Pyrazinamide; Rats; Tandem Mass Spectrometry	2014
Novel drug combination for tuberculosis to be tested across 50 sites. BMJ (Clinical research ed.), 2014, May-27, Volume: 348 Topics: Antitubercular Agents; Aza Compounds; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis	2014
Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:1 Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Pyrazinamide; Random Allocation; Tuberculosis	2015
New effective antituberculosis regimens. Lancet (London, England), 2015, May-02, Volume: 385, Issue:9979 Topics: Antitubercular Agents; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2015
Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2017, Volume: 56 Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant; World Health Organization	2017
Simultaneous HPLC assay for pretomanid (PA-824), moxifloxacin and pyrazinamide in an inhaler formulation for drug-resistant tuberculosis. Journal of pharmaceutical and biomedical analysis, 2017, Feb-20, Volume: 135 Topics: Administration, Inhalation; Antitubercular Agents; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Compounding; Fluoroquinolones; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant	2017
Estimated generic prices for novel treatments for drug-resistant tuberculosis. The Journal of antimicrobial chemotherapy, 2017, 04-01, Volume: 72, Issue:4 Topics: Algorithms; Antitubercular Agents; Commerce; Diarylquinolines; Drug Costs; Drugs, Generic; Fluoroquinolones; Humans; Moxifloxacin; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant	2017
TB Alliance regimen development for multidrug-resistant tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2016, 12-01, Volume: 20, Issue:12 Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Dose-Response Relationship, Drug; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Research Design; Rifampin; Tuberculosis, Multidrug-Resistant	2016
Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:9 Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis, Pulmonary	2017
Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:10 Topics: Antitubercular Agents; Beijing; China; Clofazimine; Diarylquinolines; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Gatifloxacin; Humans; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles	2017
Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2017, 09-01, Volume: 21, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Azithromycin; Child; Clarithromycin; Clofazimine; Diarylquinolines; Female; Fluoroquinolones; Follow-Up Studies; Humans; Lost to Follow-Up; Macrolides; Male; Middle Aged; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nitroimidazoles; Nontuberculous Mycobacteria; Oxazoles; Retrospective Studies; Tuberculosis, Multidrug-Resistant; Young Adult	2017
Antimicrobial activity against Mycobacterium tuberculosis under in vitro lipid-rich dormancy conditions. Journal of medical microbiology, 2018, Volume: 67, Issue:3 Topics: Amikacin; Anti-Bacterial Agents; Antitubercular Agents; Drug Tolerance; Fluoroquinolones; Genetic Fitness; Genotype; Humans; Lipid Metabolism; Lipids; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nitroimidazoles; Rifampin	2018
Effect of Moxifloxacin plus Pretomanid against Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:1 Topics: Antitubercular Agents; Drug Combinations; Drug Interactions; Drug Resistance, Fungal; Microbial Sensitivity Tests; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles	2019
Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis. The Indian journal of tuberculosis, 2019, Volume: 66, Issue:1 Topics: Adult; Cardiotoxicity; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Electrocardiography; Female; Humans; Imipenem; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Salvage Therapy; Sputum; Survival Rate; Tuberculosis, Multidrug-Resistant; Young Adult	2019
In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates. Journal of global antimicrobial resistance, 2019, Volume: 19 Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Drug Synergism; Extensively Drug-Resistant Tuberculosis; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Tuberculosis, Multidrug-Resistant; Xanthenes	2019
Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics. The Journal of antimicrobial chemotherapy, 2020, 02-01, Volume: 75, Issue:2 Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Mathematics; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis	2020
Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative? The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:12 Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary	2019
Tuberculosis treatment: one-shot approach or cascade of regimens? The Lancet. Respiratory medicine, 2020, Volume: 8, Issue:2 Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary	2020
Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. Antimicrobial agents and chemotherapy, 2022, 04-19, Volume: 66, Issue:4 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Isoniazid; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifabutin; Tuberculosis	2022